JAMA dermatology最新文献

{"title":"Evolution of Subacute Cutaneous Lupus Erythematosus.","authors":"Jeffrey P Callen, Courtney R Schadt","doi":"10.1001/jamadermatol.2025.1781","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.1781","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial.","authors":"Amy McMichael, Mona Shahriari, Linda Stein Gold, Theodore Alkousakis, Olivia Choi, Tina Bhutani, Adrian O Rodriguez, Stephen K Tyring, Daphne Chan, Katelyn Rowland, Lorne Albrecht, Charles Lynde, Geeta Yadav, Jensen Yeung, Laura Park-Wyllie, Tony Ma, Jenny Jeyarajah, Long-Long Gao, Stacy Smith, Angela Y Moore, Neelam Vashi, Chesahna Kindred, Pearl Grimes, Seemal R Desai, Susan C Taylor, Andrew Alexis","doi":"10.1001/jamadermatol.2025.1849","DOIUrl":"10.1001/jamadermatol.2025.1849","url":null,"abstract":"<p><strong>Importance: </strong>Varying hair textures and hair care practices contribute to nuances in clinical presentation and management of scalp psoriasis across diverse patient populations. Cohort B of the VISIBLE trial enrolled participants with moderate to severe scalp psoriasis and skin of color, across the skin-tone spectrum.</p><p><strong>Objective: </strong>To evaluate efficacy, quality of life, and adverse event outcomes of guselkumab, 100 mg, among participants with moderate to severe scalp psoriasis and skin of color over 48 weeks.</p><p><strong>Design, setting, and participants: </strong>This ongoing phase 3b, randomized clinical trial at 45 sites in the US and Canada enrolled adults with skin of color and moderate to severe scalp psoriasis (scalp surface area [SSA] ≥30%; Psoriasis Scalp Severity Index [PSSI] ≥12; scalp-specific Investigator's Global Assessment [ss-IGA] score ≥3; ≥1 nonscalp plaque). Data were collected from September 2022 to June 2024.</p><p><strong>Interventions: </strong>Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0, 4, and every 8 weeks, or placebo at weeks 0, 4, and 12, then guselkumab at weeks 16, 20, and every 8 weeks.</p><p><strong>Main outcomes and measures: </strong>Coprimary end points were ss-IGA score of 0 or 1 (ss-IGA 0/1) and 90% or greater improvement in PSSI (PSSI 90) at week 16 (guselkumab vs placebo). Major secondary end points included ss-IGA 0 (complete scalp clearance), PSSI 100, percentage changes from baseline in PSSI and SSA, changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms score, and 4-point or greater reduction in Scalp Itch Numeric Rating Scale (NRS) score.</p><p><strong>Results: </strong>Of 108 participants (81 randomized to guselkumab; 27 randomized to placebo), 100 (92.6%) completed 48 weeks of treatment. The mean (SD) age overall was 42.5 (13.6) years, and 58 participants (56.9%) were male. At the week 16 primary end point, in the guselkumab (n = 76) vs placebo (n = 26) groups, respectively, response rates were as follows: ss-IGA 0/1, 68.4% (n = 52) vs 11.5% (n = 3) (P < .001); PSSI 90, 65.8% (n = 50) vs 3.8% (n = 1) (P < .001); ss-IGA 0, 57.9% (n = 44) vs 3.8% (n = 1) (P < .001); PSSI 100, 59.2% (n = 45) vs 3.8% (n = 1) (P < .001); 4-point or greater reduction in Scalp Itch NRS score (in those with a baseline score of at least 4), 69.4% (n = 50 of 72) vs 24.0% (n = 6 of 25) (P < .001). Guselkumab efficacy increased and was maintained through week 48, when guselkumab-randomized participants achieved mean (SD) percentage improvements in PSSI and SSA of 94.6% (12.2%) and 94.8% (16.2%), respectively, and 51 (67.1%) achieved ss-IGA 0. DLQI and PSSD symptoms score least-squares mean changes were -9.7 (95% CI, -11.1 to -8.2) vs -2.2 (95% CI, -4.8 to 0.4) (P < .001) and -44.8 (95% CI, -50.6 to -39.1) vs -8.3 (95% CI, -18.4 to 1.9) (P < .001), respectively, with sustained improvements through week 48","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199185/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Climate Conditions, Weather Changes, and Air Pollutants and Atopic Dermatitis: A Meta-Analysis.","authors":"Megan Park, Samiha T Mohsen, Talia Katz, Siddhartha Sood, Sheena Maureen T Sy, Bram Rochwerg, Aaron M Drucker","doi":"10.1001/jamadermatol.2025.1790","DOIUrl":"10.1001/jamadermatol.2025.1790","url":null,"abstract":"<p><strong>Importance: </strong>Climate change and pollution are major health threats that have the potential to worsen the burden of common diseases, such as atopic dermatitis, that are affected by the environment.</p><p><strong>Objective: </strong>To summarize and assess the certainty of evidence on associations between environmental factors and atopic dermatitis outcomes.</p><p><strong>Data sources: </strong>MEDLINE, EMBASE, and Cochrane databases were systematically searched from inception to June 28, 2024.</p><p><strong>Study selection: </strong>Studies included observational studies (cohort, case-control, and cross-sectional) that assessed the association observational studies that assessed associations between climate conditions (eg, ambient air pollution, weather, and climate) and atopic dermatitis outcomes in adults 18 years and older. Searches combined Medical Subject Heading terms and keywords for atopic dermatitis and each environmental factor, with no language, date, or geographical restrictions.</p><p><strong>Data extraction and synthesis: </strong>Data were synthesized using random-effects models, with pooled estimates reported alongside 95% CIs, and the Grading of Recommendations Assessment, Development, and Evaluation was used to assess the certainty of the evidence across outcomes.</p><p><strong>Main outcomes and measures: </strong>Atopic dermatitis prevalence or severity.</p><p><strong>Results: </strong>Of 11 402 citations identified, 42 studies were included. There was an increase in atopic dermatitis outpatient clinic visits for every 10-μg/m3 increase in particulate matter 10 μm in diameter or less (risk ratio [RR], 1.008; 95% CI, 1.003-1.012; high certainty), particulate matter 2.5 μm in diameter or less (RR, 1.013; 95% CI, 0.999-1.027; moderate certainty), sulfur dioxide (RR, 1.029; 95% CI, 1.020-1.039; high certainty), and nitrogen dioxide (RR, 1.014; 95% CI, 0.999-1.030; moderate certainty). Extreme environmental temperatures (hot and cold) were are associated with increased atopic dermatitis-related clinical visits (moderate to high certainty). Higher precipitation, including rain, may be associated with increased atopic dermatitis severity (low certainty), and higher levels of humidity are probably associated with increased atopic dermatitis severity (moderate certainty). Increased duration of sunlight exposure had an uncertain association with atopic dermatitis severity (very low certainty). Secondhand smoking exposure and traffic and industrial plant exposure are probably associated with increased atopic dermatitis prevalence (moderate certainty).</p><p><strong>Conclusions and relevance: </strong>The results of this systematic review and meta-analysis suggest that increased levels of environmental pollutants and temperature extremes are associated with increased population burden of atopic dermatitis. Measures to mitigate pollution and climate change may improve atopic dermatitis outcomes.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial.","authors":"Andrew Alexis, Amy McMichael, Jennifer Soung, Olivia Choi, Theodore Alkousakis, Javier Alonso-Llamazares, Mona Shahriari, Adrian O Rodriguez, Tina Bhutani, Daphne Chan, Katelyn Rowland, Maxwell Sauder, H Chih-Ho Hong, Geeta Yadav, Jensen Yeung, Jenny Jeyarajah, Tony Ma, Long-Long Gao, Laura Park-Wyllie, Lawrence Green, Mark Lee, Neelam Vashi, Chesahna Kindred, Pearl Grimes, Susan C Taylor, Seemal R Desai","doi":"10.1001/jamadermatol.2025.1836","DOIUrl":"10.1001/jamadermatol.2025.1836","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;Data and educational gaps in populations with skin of color contribute to racial and ethnic disparities in psoriasis treatment. Cohort A of the VISIBLE study includes participants with psoriasis who self-identify as belonging to a racial or ethnic category other than White, across the entire skin-tone spectrum.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To evaluate efficacy, quality of life, and adverse event outcomes among participants with moderate to severe psoriasis and skin of color who received guselkumab, 100 mg, for up to 48 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;This ongoing phase 3b, randomized clinical trial at 39 sites in the US and Canada enrolled adults with skin of color and moderate to severe psoriasis (body surface area [BSA] ≥10%; Psoriasis Area and Severity Index [PASI] ≥12; Investigator's Global Assessment [IGA] ≥3). Data were collected from August 2022 to June 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Interventions: &lt;/strong&gt;Randomized participants (3:1) received guselkumab, 100 mg, at weeks 0 and 4, then every 8 weeks, or placebo with crossover to guselkumab at weeks 16 and 20, then every 8 weeks.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes and measures: &lt;/strong&gt;Coprimary end points were IGA score of 0 or 1 (IGA 0/1) and PASI improvement of 90% or more (PASI 90) at week 16 (guselkumab vs placebo). Major secondary end points included IGA 0; PASI 100; percentage changes from baseline in PASI and BSA; changes from baseline in Dermatology Life Quality Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD) symptoms; and at least a 4-point reduction in PSSD itch.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Of 103 participants (77 randomized to guselkumab; 26 randomized to placebo), 94 (91.3%) completed 48 weeks of treatment. The mean (SD) age overall was 44.1 (12.9) years, and 74 participants (71.8%) were male. At week 16, coprimary end points were achieved by greater proportions of guselkumab- vs placebo-treated participants (IGA 0/1: 57 of 77 [74.0%] vs 0 of 26; P &lt; .001; PASI 90: 44 of 77 [57.1%] vs 1 of 26 [3.8%]; P &lt; .001); 25 of 77 (32.5%) vs 0 of 26 achieved IGA 0 (P &lt; .001), and 23 of 77 (29.9%) vs 0 of 26 achieved PASI 100 (P = .002). DLQI and PSSD symptoms score least-squares mean changes from baseline were -12.1 (95% CI, -13.1 to -10.9) vs -2.5 (95% CI, -4.4 to -0.6) (P &lt; .001), and -49.4 (95% CI, -54.0 to -44.9) vs -8.2 (95% CI, -15.8 to -0.6) (P &lt; .001), respectively. A 4-point or greater reduction in PSSD itch score was achieved by 48 (66.7%) vs 4 (16.7%) participants with a baseline score of at least 4 (P &lt; .001). Efficacy increased and was maintained through week 48, with guselkumab-randomized participants achieving mean percentage improvements in PASI and BSA of more than 94%, and more than 50% of participants achieving complete clearance. Infections were the most common adverse events in the guselkumab (16 [20.8%]) and placebo (3 [11.5%]) groups through week 16, predominantly upper respiratory tract infection","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12199184/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484415","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Nemolizumab in Refractory Scrotal Dysesthesia.","authors":"Walter Liszewski","doi":"10.1001/jamadermatol.2025.1480","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.1480","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation.","authors":"April W Armstrong, George C Gondo, Joseph F Merola, Alyssa M Roberts, Lourdes M Pérez-Chada, Deepak M W Balak, Guy S Eakin, Charlotte Read, Stephanie T Le, Yasmin Gutierrez, Tina Bhutani, Andrew Blauvelt, Kristina Callis Duffin, Steven Fakharzadeh, Steven R Feldman, Joel M Gelfand, Dafna D Gladman, Brad Glick, Lawrence J Green, George Han, Jason E Hawkes, Samuel T Hwang, Nicole Johnsen, Robert E Kalb, Leon Kircik, Richard G Langley, Mark G Lebwohl, G Michael Lewitt, Emanual Maverakis, Ronald Prussick, Soumya M Reddy, Cheryl F Rosen, Jose U Scher, Evan L Siegel, Elizabeth B Wallace, Jeffrey M Weinberg, Paul S Yamauchi, Gil Yosipovitch, Wilson Liao","doi":"10.1001/jamadermatol.2025.1625","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.1625","url":null,"abstract":"<p><strong>Importance: </strong>Defining on-treatment remission in plaque psoriasis is important for benchmarking patient responses to therapies. This also helps to facilitate shared understanding, align treatment expectations, and enable more effective psoriasis management.</p><p><strong>Objective: </strong>To establish a consensus-based definition of on-treatment remission for plaque psoriasis through a multistage Delphi initiative.</p><p><strong>Evidence review: </strong>The Remission Workgroup from the medical board and scientific advisory board of the National Psoriasis Foundation engaged various stakeholders, both US based and international, to participate in the consensus process. Following a working group meeting to determine the overall consensus approach, a systematic review of remission definitions in the current literature was performed. This review helped to inform the content of consensus materials. The consensus effort involved 2 stages: pre-Delphi interviews and surveys to inform the Delphi questions, followed by a Delphi exercise with physicians to define on-treatment remission for plaque psoriasis. Outcome measures considered included body surface area (BSA), Investigator Global Assessment (IGA), the product of the Physician Global Assessment and body surface area (PGA × BSA), and Psoriasis Area and Severity Index (PASI) score at various cutoff levels and time points.</p><p><strong>Findings: </strong>The consensus process involved 92 stakeholders, including dermatologists, rheumatologists, researchers, patients, payers, and life sciences professionals. In the pre-Delphi interviews and surveys, patients emphasized that on-treatment remission meant the absence of psoriasis signs and symptoms while recieving therapy. Payers expressed that defining remission is important for long-term treatment coverage. Following the Delphi exercise and discussion with participating physicians specializing in psoriatic disease management, on-treatment remission in plaque psoriasis was defined as patients maintaining a BSA of 0% or IGA of 0 for at least 6 months while on treatment.</p><p><strong>Conclusions and relevance: </strong>Through a Delphi consensus process, on-treatment remission for plaque psoriasis was defined as patients maintaining a BSA involvement of 0% or IGA of 0 for at least 6 months while on treatment. This clear and standardized benchmark is applicable to both research and practice settings.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab.","authors":"Teng-Li Lin, Yi-Hsuan Fan, Kuo-Sheng Fan, Chao-Kuei Juan, Yi-Ju Chen, Chun-Ying Wu","doi":"10.1001/jamadermatol.2025.1578","DOIUrl":"10.1001/jamadermatol.2025.1578","url":null,"abstract":"<p><strong>Importance: </strong>Patients with atopic dermatitis (AD) have been reported to develop psoriasis during dupilumab treatment. Whether this represents a true association or an incidental event remains unclear.</p><p><strong>Objective: </strong>To compare psoriasis risk in patients with AD who are prescribed dupilumab vs other systemic agents.</p><p><strong>Design, setting, and participants: </strong>This population-based retrospective cohort study with 3-year follow-up, with analyses completed on October 19, 2024, included 214 430 adult patients with AD from the TriNetX Global Collaborative Network. Individuals newly prescribed dupilumab (dupilumab cohort) and those newly prescribed the other systemic agents without dupilumab exposure (control cohort) were included. Propensity score matching at a 1:1 ratio based on age, sex, race, comorbidities, laboratory measurements, and prior medications was conducted.</p><p><strong>Exposures: </strong>Dupilumab vs the other systemic agents (corticosteroids, methotrexate, cyclosporine, azathioprine, or mycophenolate mofetil).</p><p><strong>Main outcomes and measures: </strong>The primary outcome was incident psoriasis. Cumulative incidence was assessed using Kaplan-Meier plots and risks via Cox regression.</p><p><strong>Results: </strong>After matching, each cohort comprised 9860 patients, with 10 891 female individuals (55.2%), a mean (SD) age of 44.8 (20.3) years, 3582 African American or Black individuals (18.2%), 2004 Asian individuals (10.2%), and 9901 White individuals (50.2%). The 3-year cumulative psoriasis incidence was higher in the dupilumab cohort than the control cohort (2.86% vs 1.79%; P < .001). The number needed to harm for psoriasis was 94 for dupilumab vs the other systemic agents. The dupilumab cohort showed an increased risk for psoriasis (hazard ratio [HR], 1.58; 95% CI, 1.25-1.99), although the risk for psoriatic arthritis was not significant (HR, 1.97; 95% CI, 0.75-5.18). This increased risk was also observed in various AD subgroups, including those without atopic comorbidities (HR, 1.42; 95% CI, 1.06-1.89) or with pretreatment immunoglobulin E levels less than 0.048 mg/dL (to convert to mg/L, multiply by 10; HR, 1.59; 95% CI, 1.26-2.01). The association between dupilumab and psoriasis was further supported by validation in patients with asthma without AD (HR, 2.13; 95% CI, 1.38-3.31).</p><p><strong>Conclusions and relevance: </strong>The results of this cohort study suggest that patients with AD who were prescribed dupilumab exhibited a higher relative risk of developing psoriasis compared with those receiving other systemic agents. Given an estimated number needed to harm of 94, the absolute risk may have limited clinical relevance and should be weighed against dupilumab's established efficacy in treating AD.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177727/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Benzoyl Peroxide-Containing Products and Benzene: Where Are We Now After Recalls, and How Should We Move Forward?","authors":"John S Barbieri, Christopher G Bunick","doi":"10.1001/jamadermatol.2025.1694","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.1694","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Reaction With Eosinophilia and Systemic Symptoms in Children.","authors":"Lei Jiao, Yang Wang, Jing Tian, Mutong Zhao, Zigang Xu, Lin Ma, Yuan Liang","doi":"10.1001/jamadermatol.2025.1651","DOIUrl":"10.1001/jamadermatol.2025.1651","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Asymptomatic Symmetrical Telangiectasia on Lower Extremities.","authors":"Pei-Yun Ho, Yi-Tsz Lin","doi":"10.1001/jamadermatol.2025.1416","DOIUrl":"https://doi.org/10.1001/jamadermatol.2025.1416","url":null,"abstract":"","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":" ","pages":""},"PeriodicalIF":11.5,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}